Astellas Pharma Inc. has entered into a definitive agreement to acquire Ogeda SA, a privately-owned drug discovery company focused on small molecule drugs targeting G-protein coupled receptors (GPCRs), for as much as €800 million. Its lead candidate, fezolinetant, a selective NK3 receptor antagonist, achieved positive data from a Phase IIa study for the non-hormonal treatment of menopause-related vasomotor symptoms (MR-VMS). Ogeda will become a wholly owned subsidiary of Astellas. The closing, s...